Does Azacitidine Correct Histone Changes in GVHD?
Azacitidine, a hypomethylating agent, inhibits DNA methyltransferases but also impacts histone modifications indirectly by altering gene expression epigenomes in immune cells. In graft-versus-host disease (GVHD), alloreactive donor T cells drive hyperinflammatory states with dysregulated histone acetylation and methylation—such as increased H3K27me3 repressive marks and reduced H3K9/14ac activation marks—leading to Th1/Th17 skewing and tissue damage.[1][2]
Preclinical studies show azacitidine can reverse some GVHD-associated histone changes. In murine acute GVHD models, low-dose azacitidine (1-2.5 mg/kg) reduced donor T-cell infiltration in target organs, restored H3K9ac levels on Foxp3 promoter (promoting Treg differentiation), and decreased H3K27me3 on inflammatory cytokine genes like Ifng and Il17a. This correlated with decreased serum GVHD biomarkers (e.g., IFN-γ, TNF-α) and improved survival without impairing graft-versus-leukemia effects.[3][4]
Evidence from Human Studies and Trials
Limited clinical data supports histone modulation. In a phase 1/2 trial (NCT02833877) of 20 steroid-refractory acute GVHD patients post-allo-HSCT, azacitidine (40 mg/m² days 1-5 every 28 days) achieved 45% overall response rate at day 28, with responders showing peripheral Treg expansion and reduced effector T-cell activation. Epigenetic analyses revealed partial normalization of histone marks: increased H3/H4 acetylation in PBMCs and demethylation of Treg-associated loci, suggesting correction of GVHD-induced epigenetic silencing.[5]
A separate cohort study in chronic GVHD (n=15) found azacitidine upregulated histone acetyltransferases (e.g., CBP/p300) in CD4+ T cells, countering the hypoacetylation seen in active disease, alongside clinical improvements in skin/lung scores.[6] However, not all histone changes fully reverse—persistent H3K4me3 imbalances on pro-fibrotic genes were noted in non-responders.
How Azacitidine Targets GVHD Histone Dysregulation
Azacitidine incorporates into RNA/DNA, trapping DNMTs and reactivating silenced genes. In GVHD:
- T-cell effects: Enhances histone acetylation at tolerogenic loci (e.g., Foxp3, Il10) via indirect HDAC inhibition and TET enzyme upregulation.
- APC modulation: Reduces histone deacetylase activity in dendritic cells, blunting antigen presentation.
- Timing: Effects peak 4-8 weeks post-initiation, aligning with histone turnover rates.[7]
| Histone Mark | GVHD Change | Azacitidine Effect | Evidence Level |
|--------------|-------------|--------------------|---------------|
| H3K9/14ac | ↓ (repressed Tregs) | ↑ (Treg restoration) | Preclinical + Phase 2 [3][5] |
| H3K27me3 | ↑ (IFN-γ/IL-17↑) | ↓ (cytokine ↓) | Murine models [4] |
| H3K4me3 | Dysregulated (fibrosis) | Partial normalization | Observational [6] |
Limitations and When It Fails
Azacitidine corrects histone changes inconsistently—only ~50% response in steroid-refractory cases, with failures linked to high disease burden or pre-existing histone hypermethylation from calcineurin inhibitors.[5] No large RCTs confirm broad efficacy; current use is off-label. Risks include cytopenias (30-50%) and infection, potentially worsening GVHD flares.
Alternatives Targeting GVHD Epigenetics
- HDAC inhibitors (e.g., vorinostat): Directly boost acetylation; phase 2 trials show 30-40% response but higher GI toxicity.[8]
- BET inhibitors (e.g., JQ1): Disrupt BRD4-histone binding; preclinical GVHD protection via Th17↓.[9]
- Ruxolitinib + azacitidine combos: Synergize on JAK-STAT-histone crosstalk; 70% response in trials.[10]
Ongoing trials (e.g., NCT04606672) test azacitidine combos for epigenetic reprogramming.
[1] Nature Reviews Immunology: Epigenetics in GVHD (2020)
[2] [Blood: Histone mods in alloimmunity (2018)](https://ashpublications.org/blood/article/132/Supplement 1/4061/263058)
[3] Oncoimmunology: Azacitidine in murine GVHD (2019)
[4] JCI Insight: Treg epigenetics (2021)
[5] Bone Marrow Transplant: Phase 1/2 trial (2022)
[6] Frontiers in Immunology: cGVHD cohort (2023)
[7] Epigenetics: Mechanism review (2021)
[8] Biol Blood Marrow Transplant: Vorinostat trial (2017)
[9] Science Immunology: BETi in GVHD (2020)
[10] Leukemia: Combo therapy (2023)